T. Rowe wraps its analyst bench in a 47-basis-point ETF

T. Rowe Price added three fully transparent active equity ETFs to Nasdaq Thursday, lifting its active lineup to 38 funds, and the price sheet explains the strategy better than the announcement did: Mid-Cap Equity Research (TMID) at 0.47%, Biotech (TDNA) at 0.55%, Small-Cap (TSEE) at 0.59%.

TMID is the one that matters. Extending the Structured Research Strategies lineup that already holds TSPA, TIER and TEMR, TMID draws its stock selection from the firm's analysts and their "best ideas," per the company, with more than 300 stocks under Paige Davis Jr., Amanda Ludwitzke and Thomas Watson, whose investing experience totals 49 years. Priced below both of the week's siblings and in the same neighborhood as the 44 basis points on TMED, its health-care sector ETF, the analyst bench sells at 0.47%; this firm does not discount research mandates much below the mid-40s.

The other two are narrower bets at higher prices: TDNA, managed by John Hall with 11 years at the firm, targets 60 to 120 companies it identifies as treating or curing disease, while TSEE sells diversified U.S. small-cap exposure through the firm's small-cap heritage and fundamental research under Alex Roik, whose 13 years of investing experience manage a portfolio of typically 200 or more stocks. TSEE is the harder sell of the pair—broad domestic small-cap is the least differentiated mandate in the batch and carries the highest fee, where TDNA at least sells scarcity.

The three funds fill gaps rather than open fronts—the lineup already spans equity, fixed income, multi-asset and thematic strategies, per the company—which puts the emphasis exactly where this firm's ETF build has always put it. T. Rowe managed $1.90 trillion in client assets as of Aug 31, about two-thirds of it in retirement accounts that have no built-in need for the ETF wrapper. The 38 active funds exist to keep active management in front of advisors who allocate through model portfolios, the distribution play this publication described when the firm's ETF plans last went on the record. Eight launches in nine months is a bid for shelf space, and the contested commodity is advisor attention, not structure; nothing in this batch carries leverage, derivatives or a semi-transparent wrapper, so the strain of listing complex products faster than the desks behind them can price the baskets leaves these three untouched.

Which fund lands in wirehouse and RIA model portfolios first will be the tell. TMID's 47 basis points is T. Rowe's own bet on the answer.